Oramed Pharmaceuticals(ORMP)

Focus: Oramed Pharmaceuticals is a New York-based public company focused on oral drug delivery and oral biologics, with a concentrated pipeline centered on oral insulin (ORMD-0801) for diabetes and metabolic disease indications.

Neurology

Profile data last refreshed 54m ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Oramed Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Oramed Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$2M

Key Products

ORMD-0801

Type 2 Diabetes Mellitus, Type 1 Diabetes, NASH

Growth

Lead program advancing through Phase 2 and Phase 3 trials across multiple diabetes indications and NASH; represents core commercial bet for company.

Pipeline & Clinical Trials

Help build intelligence for Oramed Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering oral insulin delivery platform addresses massive unmet need in diabetes with 16 active trials and Phase 3 programs advancing
Highly R&D-intensive organization (316% R&D intensity) attracts deep scientific and development talent focused on transformative drug delivery innovation
Public company status with $54M cash position provides stability and potential for equity upside if Phase 3 trials succeed

Watch Out For

Minimal revenue generation ($2M FY2025) and operating losses ($19M FY2025) indicate pre-commercialization burn rate despite public status
Zero current open positions and historically thin headcount suggest limited hiring; execution risk concentrated on single lead asset ORMD-0801

Generated by Claude from Oramed Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

ORMD-0801 QD

Nonalcoholic Steatohepatitis (NASH)

Phase 2

Clinical Trials (1)

NCT04616014A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)

Phase 2

Oral Insulin

Non-Alcoholic Steatohepatitis (NASH)

Phase 2

Clinical Trials (1)

NCT02653300A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)

Phase 2

ORMD-0801 Capsules

Diabetes Mellitus Type 1

Phase 2

Clinical Trials (1)

NCT02094534A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics

Phase 2

ORMD-0801

Diabetes Mellitus, Type 2

Phase 2

Clinical Trials (1)

NCT04618744A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

Phase 2

ORMD-0801

Diabetes Type 2

Phase 2

Clinical Trials (1)

NCT02496000Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus

Phase 2

ORMD-0801 Treatment A

Type 1 Diabetes

Phase 2

Clinical Trials (1)

NCT04150107A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes

Phase 2

ORMD 0801

Brittle Type I Diabetes Mellitus

Phase 2

Clinical Trials (1)

NCT00867594Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients

Phase 2

ORMD-0801

Diabetes Mellitus, Type 2

Phase 2

Clinical Trials (1)

NCT04564846A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus

Phase 2

ORMD-0801

Type 2 Diabetes Mellitus

Phase 2

Clinical Trials (1)

NCT02954601A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

Phase 2

ORMD-0801 capsules- 2x8mg

Type 1 Diabetes

Phase 2

Clinical Trials (1)

NCT02535715A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)

Phase 2

Cohort A: ORMD-0801

T2DM (Type 2 Diabetes Mellitus)

Phase 2

Clinical Trials (1)

NCT03467932A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

Phase 2

ORMD-0801 Dose # 1

Diabetes Mellitus Type 2

Phase 2

Clinical Trials (1)

NCT01889667Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)

Phase 2

ORMD-0801

Diabetes Mellitus, Type 2

Phase 3

Clinical Trials (1)

NCT04817215Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Phase 3

ORMD-0801

T2DM (Type 2 Diabetes Mellitus)

Phase 3

Clinical Trials (1)

NCT04754334A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Phase 3

ORMD-0801 8 mg

Type 2 Diabetes Mellitus

Phase 3

Clinical Trials (1)

NCT06731075A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

Phase 3

Placebo

Type 2 Diabetes Mellitus

Phase 3

Clinical Trials (1)

NCT04606576Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 16 clinical trials

Top TAs: Metabolic Diseases, Infectious Diseases

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Metabolic Diseases

15 pipeline

Infectious Diseases

3 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$2M49%

R&D Spend

$6M(316%)30%

Net Income

-$19M